Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing
Davis Polk advised Laekna, Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Regulation S. The net proceeds from the offering amounted to approximately HK$791 million.
Founded in 2016, Laekna, Inc. is a science-driven, clinical-stage biotechnology company. It has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials and has initiated one clinical trial and another five clinical trials for its core products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers.
The Davis Polk corporate team included partners Xuelin (Steve) Wang, Yang Chu and Jason Xu, associates Jenny Ho and Michelle Chow and registered foreign lawyers Wentian Xie and Haiyang Zhao. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.
Related Posts
Based on the SIPS model ChangYi proposes marketing strategies for big health brands
According to the “Gen Z Nutrition Consumption Trend Report,” consumers aged 18-35 account for 83.7% of the total health and wellness market, becoming the main force driving growth. Driven by the “Healthy China” initiative and shifting health awareness, the industry is rapidly developing amid fierce competition. Marketing focus has shifte
Yizhu Technology Completes Multi-Hundred-Million RMB Financing to Drive AI Chip Innovation （October 15, 2024)
Yizhu Technology announced completion of multi-hundred-million RMB financing led by a renowned overseas fund with participation from Shengshi Technology and Xingzhi Capital. The funding will support ongoing development and innovation of AI compute chips and system solutions, focusing on overcoming the “memory wall” and “energy wall” for
FDA Approves IND for LAE120, a Novel USP1 Inhibitor for Advanced Solid Tumors (March 4, 2025)
In March 2025, Laekna announced that the FDA approved the IND for LAE120, a novel USP1 inhibitor developed internally for advanced solid tumors. LAE120 shows potent monotherapy anti-tumor activity and synergy with PARP inhibitors, especially in homologous recombination deficiency (HRD) cancers. It demonstrated strong tumor inhibition in various xenograft models
Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare
NEW YORK (GenomeWeb) – Hong Kong-based venture capital group ORI Healthcare Fund announced today that it has made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences. According to ORI, Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which offer